These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30500945)

  • 1. Noninvasive, Targeted Creation of Neuromyelitis Optica Pathology in AQP4-IgG Seropositive Rats by Pulsed Focused Ultrasound.
    Yao X; Adams MS; Jones PD; Diederich CJ; Verkman AS
    J Neuropathol Exp Neurol; 2019 Jan; 78(1):47-56. PubMed ID: 30500945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.
    Yao X; Verkman AS
    Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G.
    Yao X; Verkman AS
    Acta Neuropathol Commun; 2017 Jul; 5(1):57. PubMed ID: 28750658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
    Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
    J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica.
    Duan T; Smith AJ; Verkman AS
    J Neuroinflammation; 2018 Oct; 15(1):294. PubMed ID: 30348195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.
    Asavapanumas N; Verkman AS
    Acta Neuropathol Commun; 2014 Apr; 2():48. PubMed ID: 24758159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.
    Tradtrantip L; Duan T; Yeaman MR; Verkman AS
    J Neuroinflammation; 2019 Mar; 16(1):57. PubMed ID: 30851734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica.
    Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS
    Neuropharmacology; 2018 May; 133():345-353. PubMed ID: 29428821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity.
    Duan T; Smith AJ; Verkman AS
    Acta Neuropathol Commun; 2019 Jul; 7(1):112. PubMed ID: 31296268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.
    Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS
    Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema.
    Ratelade J; Bennett JL; Verkman AS
    PLoS One; 2011; 6(11):e27412. PubMed ID: 22076159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica pathogenesis and aquaporin 4.
    Graber DJ; Levy M; Kerr D; Wade WF
    J Neuroinflammation; 2008 May; 5():22. PubMed ID: 18510734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G.
    Asavapanumas N; Ratelade J; Papadopoulos MC; Bennett JL; Levin MH; Verkman AS
    J Neuroinflammation; 2014 Jan; 11():16. PubMed ID: 24468108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.
    Rossi A; Ratelade J; Papadopoulos MC; Bennett JL; Verkman AS
    Glia; 2012 Dec; 60(12):2027-39. PubMed ID: 22987455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in multiple sclerosis research: astrocytopathy in demyelinating diseases].
    Kira J
    Rinsho Shinkeigaku; 2010 Nov; 50(11):788-93. PubMed ID: 21921443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.
    Ratelade J; Verkman AS
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1519-30. PubMed ID: 22713791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.
    Ratelade J; Asavapanumas N; Ritchie AM; Wemlinger S; Bennett JL; Verkman AS
    Acta Neuropathol; 2013 Nov; 126(5):699-709. PubMed ID: 23995423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
    Jarius S; Wildemann B
    Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Neuromyelitis Optica Immunoglobulin G Binding to Aquaporin-4 by the Small Molecule Blocker Melanthioidine.
    Xu H; Gong Y; Jiao Y; Guo J; Zhao L; Yang J; Tong H; Sun M; Li M
    Curr Pharm Des; 2023; 29(10):793-802. PubMed ID: 36998134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.